Octet RH96 High-throughput BLI plate reader

The U.S. Food and Drug Administration's Center for Drug Evaluation and Research is procuring an Octet RH96 High-throughput Biolayer Interferometry (BLI) plate reader to support pharmaceutical quality research activities. The instrument must provide label-free detection capabilities and analyze up to 96 samples simultaneously for high-throughput potency assays, antibody titer measurement, host cell protein quantitation, residual Protein A detection, and kinetic analyses. The required system includes the Octet RED96e Rapid Extended System with instrument, computer, software license, and specialized accessories including Protein A Biosensors, Host Cell Protein Detection Kit, and High-Precision Streptavidin Biosensors. The government will evaluate proposals based on technical compliance and price factors, with both criteria weighted approximately equally, and expects to select the best-suited vendor from initial responses without extensive negotiations. Vendors must submit questions by August 1, 2025, and complete two-volume proposals (Technical and Price) by August 5, 2025.

This procurement is designated as a total small business set-aside under NAICS code 334516 (Analytical Laboratory Instrument Manufacturing). The contract requires delivery within 60 calendar days after award, with installation and training to be completed within six weeks of shipment to the FDA CDER facility in Silver Spring, Maryland. The performance period spans one year beginning from delivery and installation of the equipment. No incumbent contractors or specific award values are identified in the solicitation documents. The procurement represents a specialized scientific instrument acquisition focused on supporting the FDA's pharmaceutical quality research mission through advanced biolayer interferometry technology.